1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

Abstract

Osimertinib has shown robust survival benefit in advanced EGFR-mutant NSCLC. However, ≈ 15% of these patients experience disease progression within 6 months of therapy, and there is a need to identify targetable resistance mechanisms.